Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Powder Developed to Enhance NMR Signals for Faster, Better Structure Determination and Early Cancer MRI Diagnosis

By BiotechDaily International staff writers
Posted on 22 Jan 2014
Print article
Image: Schematic of polarization process: Polarizing Agent (powder) (left), Molecule (red), Microwave (top), Nuclear Magnetic Resonance (bottom), Hyperpolarization of the targeted molecule (left) (Photo courtesy of the University of Lyon, France).
Image: Schematic of polarization process: Polarizing Agent (powder) (left), Molecule (red), Microwave (top), Nuclear Magnetic Resonance (bottom), Hyperpolarization of the targeted molecule (left) (Photo courtesy of the University of Lyon, France).
Dynamic nuclear polarization (DNP) combined with nuclear magnetic resonance (NMR) allows, due to polarizing agents, the enhancement of NMR signals from a wide range of molecules resulting in the substantial reduction of the NMR acquisition time. It reveals, therefore, strong advantages over conventional NMR and possibly over X-ray diffraction techniques used to characterize proteins on synchrotron type equipment.

NMR spectroscopy is an extremely powerful nondestructive technique for the characterization of molecules. Widely used by chemists from its early beginnings, it is now essential in the synthesis and analysis laboratories and its scope extends into biologic laboratories.

NMR has also known an exciting new advance in the medical field with the development of magnetic resonance imaging (MRI). Up to now, the DNP has been effectively applied to MRI for the early diagnosis of tumors in small animals (pigs and rodents) in preclinical research and more recently to 30 human patients having prostate cancers. However, MRI using DNP cannot be generalized to human diagnosis because polarizing agents used to activate biologic tracers/contrast agents need to be quantitatively separated from the polarized solution before human injection and image acquisition. This technical hurdle is now solved.

In this framework, an innovative powder for the easy polarization of many molecules, including biologic tracers, was developed in the frame of a European collaboration involving the University of Lyon’s laboratory of chemistry, catalysis, polymers and processes (UMR 5265-LC2P2), the European Center for High-Field NMR (UMR 5280, CRMN; Lyon, France) and ETH (Swiss Federal Institute of Technology) Zurich (Switzerland). These novel powders are creating tools for the fast characterization of complex systems by means of solid state NMR using DNP but also in the field of medical imaging for early cancer diagnosis using MRI. In this latter field, these agents can deliver a solution of polarized biologic tracers/contrast agents that are free from any impurity and therefore safe to inject in humans.

The research was published August 2013 in Journal of the American Chemical Society.

Related Links:

University of Lyon
European Center for High-Field NMR
ETH Zurich



Print article

Channels

Drug Discovery

view channel
Image: A scanning electron microscope (SEM) image of methicillin-resistant Staphylococcus aureus bacteria (Photo courtesy of the CDC).

Drug Combination Cures MRSA Infection While Preventing Development of Resistance

Treatment with a combination comprising the well-known antibiotic cefdinir and the experimental drug TXA709 cured mice of drug-resistant staphylococcal infections while reducing the development of resistance.... Read more

Biochemistry

view channel
Image: A space-filling model of the anticonvulsant drug carbamazepine (Photo courtesy of Wikimedia Commons).

Wastewater May Contaminate Crops with Potentially Dangerous Pharmaceuticals

Reclaimed wastewater used to irrigate crops is contaminated with pharmaceutical residues that can be detected in the urine of those who consumed such produce. Investigators at the Hebrew University... Read more

Lab Technologies

view channel
Image: A three-dimensional printer adapted for stem cell production (Photo courtesy of Nano Dimension).

Israeli Developers Demonstrate Prototype Three-Dimensional Bioprinter

Two Israeli companies have combined efforts in the development of three-dimensional printer technology for the production of stem cells. The three-dimensional print electronics developer Nano Dimension... Read more

Business

view channel

Acquisition to Boost Development of Drugs for Neurogenic Conditions

According to a recent announcement, a privately held biotechnology/drug development company is to be acquired by one of the major pharmaceutical manufacturers. The drug manufacturer Merck & Co. (Kenilworth, NJ, USA) has agreed to pay 500 million USD up front for Afferent Pharmaceuticals (San Mateo, CA, USA) and up... Read more
Copyright © 2000-2016 Globetech Media. All rights reserved.